INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 123,601 | $953.83 | 801,608 |
| Dec 12, 2018 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 129,013 | -- | 129,013 |
| Feb 15, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 129,902 | $8.50 | 962,943 |
| Feb 15, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 129,902 | -- | 3,430 |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 129,902 | -- | 129,902 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 130,714 | $483.25 | 750,224 |
| Dec 12, 2017 |
Director, President & CSO
|
Director, President & CSO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 139,474 | -- | 139,474 |
| Dec 16, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 146,815 | -- | 146,815 |
| Dec 16, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 146,815 | -- | 146,815 |
| Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.